文献速递血液净化与透析

递增式腹膜透析处方模式与结局:支持共同决策

Evaluating Patterns and Outcomes in the Prescription of Incremental Peritoneal Dialysis in Support of Shared Decision Making.
PubMed 文献 · Clin J Am Soc Nephrol · 2026-08-25

单中心回顾性队列纳入527例初始递增式PD患者,1年时64%维持原起始处方,2年时36%未递增。年轻、男性、低白蛋白与更短递增时间相关,转HD与死亡低,支持递增式PD安全性。

要点

  • 递增式PD患者1年内多无需调整起始处方,2年36%仍未递增。
  • 年轻、男性、低白蛋白者递增时间更短,需提前沟通预期。
  • 转HD与死亡发生率低,支持递增式PD处方的安全性。

核心结论

  • 年轻、男性、透析起始低白蛋白与更短递增时间相关。
  • 本队列转HD与死亡发生率低,支持递增式PD处方的安全性。
  • 构建的简易临床评分需未来研究验证。

研究设计与样本

  • 单中心回顾性队列,2012年1月1日至2023年12月31日纳入527例初始递增式PD患者。
  • 随访处方变更、模式转换与死亡,用多因素Cox回归和Kaplan-Meier法分析。

主要发现

  • 1年时64%(95%CI 60%–69%)维持原起始处方,2年时36%(95%CI 31%–41%)未递增。
  • 递增时间更短与年轻(每十年HR 0.92,95%CI 0.85–0.99,P=0.02)、男性(HR 1.67,95%CI 1.29–2.16,P<0.001)、低白蛋白(HR 0.96,95%CI 0.94–0.98,P<0.001)相关。
  • PD模式转换由生活方式、容量超负荷和尿毒症症状驱动。
  • 转HD与年轻(P=0.03)和糖尿病(P=0.04)相关,转HD时间与低白蛋白(P=0.01)和起始eGFR(P=0.006)相关。
  • 死亡率为0.11事件/人年。

临床怎么用

  • 递增式PD可作为初始处方选项,1年内多无需调整,需向患者说明2年时约36%仍未递增。
  • 年轻、男性、低白蛋白患者递增可能更早,应加强预期沟通与监测。

局限性

  • 单中心回顾性设计,结果外推需谨慎。
  • 简易临床评分需未来研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KEY POINTS: Most people on incremental peritoneal dialysis did not require changes to their starting prescription within the first 12 months. Age, male sex, and lower serum albumin at dialysis start were associated with the timing of dialysis prescription increments. Low rates of transfer to hemodialysis and death rates confirmed the safety of incremental peritoneal dialysis regimens. INTRODUCTION: Incremental peritoneal dialysis (PD), where less than full-dose prescriptions are increased as residual kidney function declines, contributes to increased quality of life and reduced dialysis burden. Evidence supporting the safety of incremental regimens and informing patient expectations is limited. This study examined time to increment in dialysis prescriptions, PD modality transfer, transfer to hemodialysis, and mortality rates within a single center delivering incremental PD. METHODS: Patients incident to PD and on incremental regimens were followed for changes in prescription, modality transfer, and death between January 1, 2012, and December 31, 2023. Multivariable Cox regression assessed factors associated with time to increment, and Kaplan-Meier methods with log-rank testing were used for time-to-event analyses. RESULTS: The cohort included 527 patients. At 1 year, 64% (95% confidence interval [CI], 60% to 69%) remained on the same starting regimen, with 36% of people (95% CI, 31% to 41%) having not incremented by 2 years. Time to increment was shorter for younger age at PD start (per decade, hazard ratio [HR], 0.92; 95% CI, 0.85 to 0.99; P = 0.02), male sex (HR, 1.67; 95% CI, 1.29 to 2.16; P < 0.001), and lower serum albumin (HR, 0.96; 95% CI, 0.94 to 0.98; P < 0.001). PD modality transfer was driven by lifestyle, fluid overload, and uremic symptoms. Transfer to hemodialysis was associated with younger age ( P = 0.03) and diabetes mellitus ( P = 0.04), while time to hemodialysis transfer was correlated with lower albumin ( P = 0.01) and starting eGFR ( P = 0.006). Mortality rates were low at 0.11 events per person-year. CONCLUSION: Younger age, male sex, and lower albumin at dialysis start are associated with a shorter time to increment. Low rates of transfer to hemodialysis and death rates in this cohort support the safety of incremental PD prescribing. A simple clinical score was subsequently constructed and tested as a method of supporting shared decision making and informing patient expectations of treatment, but requires validation in future studies.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Selwood J, Shuaib R, FitzGerald TJ, et al. Evaluating Patterns and Outcomes in the Prescription of Incremental Peritoneal Dialysis in Support of Shared Decision Making. Clin J Am Soc Nephrol. 2026. PMID: 42640739. doi:10.2215/CJN.0000001187

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。